When Elliott turns up (or doesn't)...

Monday, 9 December 2019, 5:03 pm

Paul Singer's Elliott Management/Advisors started shaking the tree at Alexion last week, demaning a "proactive" sale of the $25 bilion US biopharmaceutical company.

Betaville wasn't too surprised to see the activist hedge fund make Alexion it's latest target as this website's RARE sources were suggesting in summer that both US-listed Amgen and Switzerland's Roche were (or perhaps still are?) targeting Alexion with a view to making formal offers for the company...


Register for free to see rest of this article and all public articles from Betaville

Login / Register

[Disclaimer - the information on Betaville does not consitute any form of investment recommendation and is not intended to be relied upon by readers in making, or refraining from, any investment decisions].

Post Comment